You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Oesophageal cancer

Durvalumab with chemotherapy for neoadjuvant and adjuvant treatment then alone for adjuvant treatment of resectable gastric or gastro-oesophageal junction adenocarcinoma

  • Technology appraisal guidance
  • Reference number: TA1160
  • Published:  03 June 2026
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Resource impact
  2. Guidance into practice

Tools and resources

Tools and resources to help you put the guidance into practice.

Resource impact

  • Resource impact template (Excel 863 KB)

    Published:
    03 June 2026
  • Resource impact summary report

Guidance into practice

  • About the Into practice guide

  • Practical steps to improving the quality of care and services using NICE guidance

Back to top